Viewing Study NCT00193323



Ignite Creation Date: 2024-05-05 @ 11:58 AM
Last Modification Date: 2024-10-26 @ 9:17 AM
Study NCT ID: NCT00193323
Status: COMPLETED
Last Update Posted: 2010-06-28
First Post: 2005-09-12

Brief Title: Weekly Docetaxel Versus Weekly DocetaxelGemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients
Sponsor: SCRI Development Innovations LLC
Organization: SCRI Development Innovations LLC

Study Overview

Official Title: A Randomized Phase III Comparison of Weekly Docetaxel Versus Weekly DocetaxelGemcitabine in the Treatment of Elderly or Poor Performance Status Patients With Advanced Non-Small Cell Lung Cancer
Status: COMPLETED
Status Verified Date: 2009-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: In this randomized trial we attempt to further define optimal palliative chemotherapy for elderly patients with advanced non-small cell lung cancer by comparing single agent treatment with weekly docetaxel versus combination therapy with weekly docetaxel plus gemcitabine
Detailed Description: Upon determination of eligibility patients will be randomly assigned to one of two treatment arms

Docetaxel Docetaxel Gemcitabine

For ever 2 patients treated 1 will receive treatment A docetaxel and 1 will receive treatment B Docetaxel Gemcitabine The study is not blinded so both the patient and the doctor will know which treatment has been assigned

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
104864-450 None None None